CN100424082C - 作为尿压素ⅱ受体拮抗剂的4-(哌啶基-吡咯烷基-烷基-脲基)-喹啉类化合物 - Google Patents

作为尿压素ⅱ受体拮抗剂的4-(哌啶基-吡咯烷基-烷基-脲基)-喹啉类化合物 Download PDF

Info

Publication number
CN100424082C
CN100424082C CNB028277767A CN02827776A CN100424082C CN 100424082 C CN100424082 C CN 100424082C CN B028277767 A CNB028277767 A CN B028277767A CN 02827776 A CN02827776 A CN 02827776A CN 100424082 C CN100424082 C CN 100424082C
Authority
CN
China
Prior art keywords
methyl
ethyl
quinolyl
nitrogen
urea groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028277767A
Other languages
English (en)
Chinese (zh)
Other versions
CN1617869A (zh
Inventor
哈米德·艾萨维
克里斯托夫·宾克特
马丁内·克洛泽尔
博里斯·马蒂斯
克劳斯·米勒
奥利弗·内勒
米夏埃尔·舍茨
约尔格·韦尔克
托马斯·韦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1617869A publication Critical patent/CN1617869A/zh
Application granted granted Critical
Publication of CN100424082C publication Critical patent/CN100424082C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028277767A 2001-12-04 2002-12-02 作为尿压素ⅱ受体拮抗剂的4-(哌啶基-吡咯烷基-烷基-脲基)-喹啉类化合物 Expired - Fee Related CN100424082C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP01/14195 2001-12-04
EP0114195 2001-12-04

Publications (2)

Publication Number Publication Date
CN1617869A CN1617869A (zh) 2005-05-18
CN100424082C true CN100424082C (zh) 2008-10-08

Family

ID=8164711

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028277767A Expired - Fee Related CN100424082C (zh) 2001-12-04 2002-12-02 作为尿压素ⅱ受体拮抗剂的4-(哌啶基-吡咯烷基-烷基-脲基)-喹啉类化合物

Country Status (18)

Country Link
US (1) US7375227B2 (de)
EP (1) EP1499607B1 (de)
CN (1) CN100424082C (de)
AT (1) ATE312090T1 (de)
AU (1) AU2002358071B2 (de)
CA (1) CA2473892C (de)
CY (1) CY1104993T1 (de)
DE (1) DE60207894T2 (de)
DK (1) DK1499607T3 (de)
ES (1) ES2254772T3 (de)
HU (1) HUP0402184A2 (de)
IL (1) IL162851A0 (de)
MX (1) MXPA04006599A (de)
NO (1) NO20042844L (de)
NZ (1) NZ534046A (de)
SI (1) SI1499607T1 (de)
WO (1) WO2003048154A1 (de)
ZA (1) ZA200405348B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094716A1 (en) * 2002-09-17 2006-05-04 Actelion Pharmaceuticals Ltd 1-Pyridin-4-yl-urea derivatives
WO2004099179A1 (en) * 2003-05-07 2004-11-18 Actelion Pharmaceuticals Ltd Piperazine-alkyl-ureido derivatives
US20070010516A1 (en) * 2003-05-08 2007-01-11 Hamed Aissaoui Novel piperidine derivatives
ATE427748T1 (de) * 2003-09-26 2009-04-15 Actelion Pharmaceuticals Ltd Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
DE10358539A1 (de) * 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
DE602005020314D1 (de) 2004-08-25 2010-05-12 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
CA2583845C (en) * 2004-10-12 2013-03-26 Actelion Pharmaceuticals Ltd 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US20070043104A1 (en) * 2005-06-10 2007-02-22 Luthman Ingrid K UII-modulating compounds and their use
WO2007093540A1 (en) 2006-02-17 2007-08-23 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5ht2/d3 modulators
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
CN101535258B (zh) 2006-10-31 2012-12-05 弗·哈夫曼-拉罗切有限公司 5ht2a和d3受体的醚衍生物双重调节剂
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JP2010527367A (ja) 2007-05-15 2010-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウロテンシンｉｉ受容体アンタゴニスト
AU2008256803A1 (en) * 2007-05-24 2008-12-04 Wyeth Azacyclylbenzamide derivatives as histamine-3 antagonists
WO2009004427A2 (en) * 2007-06-29 2009-01-08 Pfizer Inc. Benzimidazole derivatives
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090186567A1 (en) * 2008-01-17 2009-07-23 Xavier Orlhac Abrasive Tool With Mosaic Grinding Face
CN102757447B (zh) * 2011-07-05 2014-12-31 北京大学 一种尿素通道蛋白抑制剂及其制备方法与应用
KR101468207B1 (ko) 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR101508214B1 (ko) * 2013-03-07 2015-04-07 한국화학연구원 신규한 아졸-접합 피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
FR3008619B1 (fr) * 2013-07-16 2018-04-20 Centre Hospitalier Universitaire De Rouen Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne
BR112017015760A2 (pt) 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
CN107922384A (zh) * 2015-07-29 2018-04-17 埃斯蒂文博士实验室股份有限公司 对疼痛具有多模式活性的酰胺衍生物
CN109306151B (zh) * 2018-08-31 2020-08-14 大连理工大学 一种不含醚氧键型聚合物阴离子交换膜及其制备方法
CN112830897B (zh) * 2019-11-22 2022-09-09 石家庄以岭药业股份有限公司 含脲基苯并咪唑类衍生物及其制备方法和应用
CN116139140A (zh) * 2021-11-19 2023-05-23 中国医学科学院药物研究所 一种化合物在治疗糖皮质激素不良反应中的用途
CN115677551A (zh) * 2021-12-28 2023-02-03 武汉市振邦生物科技有限公司 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045700A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
WO2001045711A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
ES2260036T3 (es) 1999-07-28 2006-11-01 Kirin Beer Kabushiki Kaisha Derivados de urea como inhibidores del receptor ccr-3.
AU2441801A (en) 1999-12-21 2001-07-03 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
WO2001066143A1 (fr) 2000-03-07 2001-09-13 Takeda Chemical Industries, Ltd. Agents vasoactifs
EP1310490A4 (de) 2000-07-04 2004-03-17 Takeda Chemical Industries Ltd Gpr14-antagonisten
EP1351688A4 (de) 2000-12-11 2006-01-04 Smithkline Beecham Corp Urotensin-ii rezeptorantagonisten
JP2004524295A (ja) 2001-01-26 2004-08-12 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
WO2002078641A2 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
WO2002078707A1 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
US20040152692A1 (en) 2001-03-29 2004-08-05 Dashyant Dhanak Pyrrolidine sulfonamides
US20040082566A1 (en) 2001-03-29 2004-04-29 Dashyant Dhanak Pyrrolidine sulfonamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045700A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
WO2001045711A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists

Also Published As

Publication number Publication date
AU2002358071B2 (en) 2008-06-12
NO20042844L (no) 2004-08-23
ES2254772T3 (es) 2006-06-16
EP1499607B1 (de) 2005-12-07
CN1617869A (zh) 2005-05-18
US7375227B2 (en) 2008-05-20
AU2002358071A1 (en) 2003-06-17
CA2473892C (en) 2010-09-21
DE60207894T2 (de) 2006-07-20
MXPA04006599A (es) 2004-12-07
WO2003048154A1 (en) 2003-06-12
IL162851A0 (en) 2005-11-20
DE60207894D1 (en) 2006-01-12
US20050043535A1 (en) 2005-02-24
EP1499607A1 (de) 2005-01-26
DK1499607T3 (da) 2006-04-18
NZ534046A (en) 2006-02-24
ZA200405348B (en) 2005-12-28
SI1499607T1 (sl) 2006-06-30
CY1104993T1 (el) 2010-03-03
ATE312090T1 (de) 2005-12-15
CA2473892A1 (en) 2003-06-12
HUP0402184A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
CN100424082C (zh) 作为尿压素ⅱ受体拮抗剂的4-(哌啶基-吡咯烷基-烷基-脲基)-喹啉类化合物
JP3133073B2 (ja) 成長ホルモンの放出を促進するジペプチド類
US6815451B2 (en) 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
CN101203489B (zh) 羟吲哚衍生物
KR101128140B1 (ko) 멜라노코르틴-4 수용체 길항제로서의 치환된 이미다조피리딘 유도체
US20060094716A1 (en) 1-Pyridin-4-yl-urea derivatives
JP4851328B2 (ja) 新規なピリジン誘導体
JP2007506692A6 (ja) 新規なピリジン誘導体
JP2006520361A (ja) メラノコルチン−４受容体調節物質としての置換ピペリジンおよびピペラジン誘導体
US20210115011A1 (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
JP2006525273A (ja) 新規なピペラジン誘導体
JP4812758B2 (ja) Ｆｋｂｐ結合組成物及びその医薬上の使用
RU2797345C2 (ru) Новые соединения пиридинов и пиразинов в качестве ингибиторов каннабиноидного рецептора 2
JP2006052181A (ja) 新規なキノリン誘導体
US20070010516A1 (en) Novel piperidine derivatives
EP1641776A1 (de) Neue piperidinderivate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081008

Termination date: 20151202

EXPY Termination of patent right or utility model